QNCX

Quince Therapeutics has announced the acquisition of Orphai and a concurrent private placement of up to $187 million to advance its pulmonary pipeline. The deal combines an M&A transaction with a significant capital raise, signaling a strategic expansion into or deepening of pulmonary disease programs. No financial terms of the Orphai acquisition were disclosed in the headline.

Quince Therapeutics has acquired Orphai Therapeutics and announced a private placement of up to $187 million to advance its pulmonary pipeline. The deal adds Orphai's lead asset LAM-001, an inhaled rapamycin (mTOR inhibitor) targeting rare pulmonary diseases, to Quince's pipeline. New Phase 2 data for LAM-001 were recently presented at the American Thoracic Society conference.